Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…
Rakuten Medical, Inc.
(https://rakuten-med.com) 📸 Data Snapshot: June 19, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Rakuten Medical – To conquer cancer. (https://rakuten-med.com)
Title
Rakuten Medical – To conquer cancer.
Meta
Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox™ technology platform which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis.Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives.
H2 Press Release
H2 Rakuten Medical Stories
H2 Letter from Our CEO
H2 Letter fromOur CEO
H2 Our Mission
H3 Rakuten Medical Announces Executive Leadership Transition to Enhance Operational Execution and Organizational Discipline as a Global, Scalable Biotech Company
H3 Rakuten Medical Presents New Data on ASP-1929 Photoimmunotherapy as Monotherapy for Recurrent Head and Neck Cancer at ASCO 2026
H3 Rakuten Medical’s 2nd R&D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy
H3 Rakuten Medical R&D Day shared comprehensive overview of investigational Alluminox™ platform and the promising scientific and clinical data for ASP-1929/RM-1929 based on the platform
H3 Rakuten Medical Announces Executive Leadership Transition to Enhance Operational Execution and Organizational Discipline as a Global, Scalable Biotech Company
H3 Rakuten Medical Presents New Data on ASP-1929 Photoimmunotherapy as Monotherapy for Recurrent Head and Neck Cancer at ASCO 2026
H3 Rakuten Medical Announces Two Poster Presentations and Exhibit Booth at ASCO 2026 Annual Meeting
H3 Rakuten Medical’s 2nd R&D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy
H3 Rakuten Medical R&D Day shared comprehensive overview of investigational Alluminox™ platform and the promising scientific and clinical data for ASP-1929/RM-1929 based on the platform
H3 Rakuten Medical aims to transform head and neck cancer treatments in India
H3 Help came too late for my father
H3 Help came too late for my father
H3 Mission
H3 Vision
H3 Focus
H3 About Us
H3 Alluminox®
H3 Alluminox®
H3 Pipeline
H3 Partnering
H3 Partnering
H3 News
H3 Careers
H3 Contact
H3 Careers
H3 Contact
H4 Privacy Overview
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Rakuten Medical – To conquer cancer. (https://rakuten-med.com/us/)
Title
Rakuten Medical – To conquer cancer.
Meta
Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox™ technology platform which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis.Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives.
H2 Press Release
H2 Rakuten Medical Stories
H2 Letter from Our CEO
H2 Letter fromOur CEO
H2 Our Mission
H3 Rakuten Medical Announces Executive Leadership Transition to Enhance Operational Execution and Organizational Discipline as a Global, Scalable Biotech Company
H3 Rakuten Medical Presents New Data on ASP-1929 Photoimmunotherapy as Monotherapy for Recurrent Head and Neck Cancer at ASCO 2026
H3 Rakuten Medical’s 2nd R&D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy
H3 Rakuten Medical R&D Day shared comprehensive overview of investigational Alluminox™ platform and the promising scientific and clinical data for ASP-1929/RM-1929 based on the platform
H3 Rakuten Medical Announces Executive Leadership Transition to Enhance Operational Execution and Organizational Discipline as a Global, Scalable Biotech Company
H3 Rakuten Medical Presents New Data on ASP-1929 Photoimmunotherapy as Monotherapy for Recurrent Head and Neck Cancer at ASCO 2026
H3 Rakuten Medical Announces Two Poster Presentations and Exhibit Booth at ASCO 2026 Annual Meeting
H3 Rakuten Medical’s 2nd R&D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy
H3 Rakuten Medical R&D Day shared comprehensive overview of investigational Alluminox™ platform and the promising scientific and clinical data for ASP-1929/RM-1929 based on the platform
H3 Rakuten Medical aims to transform head and neck cancer treatments in India
H3 Help came too late for my father
H3 Help came too late for my father
H3 Mission
H3 Vision
H3 Focus
H3 About Us
H3 Alluminox®
H3 Alluminox®
H3 Pipeline
H3 Partnering
H3 Partnering
H3 News
H3 Careers
H3 Contact
H3 Careers
H3 Contact
H4 Privacy Overview
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Press Releases – Rakuten Medical – To conquer cancer. (https://rakuten-med.com/us/news/press-releases/)
Title
Press Releases – Rakuten Medical – To conquer cancer.
H1 Press Releases
H2 All
H2 Related Content
H3 Rakuten Medical Announces Executive Leadership Transition to Enhance Operational Execution and Organizational Discipline as a Global, Scalable Biotech Company
H3 Rakuten Medical Presents New Data on ASP-1929 Photoimmunotherapy as Monotherapy for Recurrent Head and Neck Cancer at ASCO 2026
H3 Rakuten Medical Announces Two Poster Presentations and Exhibit Booth at ASCO 2026 Annual Meeting
H3 Rakuten Medical Presents New Preclinical Findings at AACR 2026 Showing COX‑2 Inhibition Reduces Photoimmunotherapy‑Induced Edema via PGE₂ Suppression
H3 Rakuten Medical Announces First Patient Treated in Ukraine in Global Phase 3 Trial of ASP-1929 Photoimmunotherapy + Pembrolizumab for 1L Recurrent Head and Neck Cancer
H3 Year Archive
H3 Rakuten Medical Stories
H3 Press Kit
H3 About Us
H3 Alluminox®
H3 Alluminox®
H3 Pipeline
H3 Partnering
H3 Partnering
H3 News
H3 Careers
H3 Contact
H3 Careers
H3 Contact
H4 Privacy Overview
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Rakuten Medical Stories – Rakuten Medical – To conquer cancer. (https://rakuten-med.com/us/news/stories/)
Title
Rakuten Medical Stories – Rakuten Medical – To conquer cancer.
H1 Rakuten Medical Stories
H2 All
H2 Related Content
H3 September 19, 2023
H3 April 17, 2023
H3 December 5, 2022
H3 November 29, 2022
H3 December 1, 2021
H3 April 22, 2020
H3 Year Archive
H3 Press Releases
H3 Press Kit
H3 About Us
H3 Alluminox®
H3 Alluminox®
H3 Pipeline
H3 Partnering
H3 Partnering
H3 News
H3 Careers
H3 Contact
H3 Careers
H3 Contact
H4 Privacy Overview
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://rakuten-med.com) Rakuten Medical – To conquer cancer.
Image provided by Rush University Medical Center Image provided by Rush University Medical Center [H2] Press Release June 9, 2026 [H3] Rakuten Medical Announces Executive Leadership Transition to Enhance Operational Execution and Organizational Discipline as a Global, Scalable Biotech Company May 30, 2026 [H3] Rakuten Medical Presents New Data on ASP-1929 Photoimmunotherapy as Monotherapy for Recurrent Head and Neck Cancer at ASCO 2026 View all [H2] Rakuten Medical Stories September 19, 2023 [H3] Rakuten Medical’s 2nd R&D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy April 17, 2023 [H3] Rakuten Medical R&D Day shared comprehensive overview of investigational Alluminox™ platform and the promising scientific and clinical data for ASP-1929/RM-1929 based on the platform View all Press Release Rakuten Medical Stories June 9, 2026 [H3] Rakuten Medical Announces Executive Leadership Transition to Enhance Operational Execution and Organizational Discipline as a Global, Scalable Biotech Company May 30, 2026 [H3] Rakuten Medical Presents New Data on ASP-1929 Photoimmunotherapy as Monotherapy for Recurrent Head and Neck Cancer at ASCO 2026 April 30, 2026 [H3] Rakuten Medical Announces Two Poster Presentations and Exhibit Booth at ASCO 2026 Annual Meeting View all September 19, 2023 [H3] Rakuten Medical’s 2nd R&D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy April 17, 2023 [H3] Rakuten Medical R&D Day shared comprehensive overview of investigational Alluminox™ platform and the promising scientific and clinical data for ASP-1929/RM-1929 based on the platform December 5, 2022 [H3] Rakuten Medical aims to transform head and neck cancer treatments in India View all The Alluminox® platform is an investigational platform based on a cancer therapy called photoimmunotherapy, which was developed by Dr. Hisataka Kobayashi and team from the National Cancer Institute in the United States. Rakuten Medical is currently developing the Alluminox® platform as a technology consisting of an investigational drug, device and other related components. Read more [H2] Letter from Our CEO [H3] Help came too late for my father [H2] Letter fromOur CEO [H3] Help came too late for my father While my wish to save my father from the debilitating effects of cancer may have not come true, the experience inspired in me the determination to work to discover new ways to save the lives of other cancer patients around the world. That same determination is the lifeforce behind Rakuten Medical. Read more [H2] Our Mission Our first objective is to create and bring to market drugs and devices to treat cancers based on the Alluminox® platform. Our purpose is to develop the Alluminox® platform as an alternative technology in the fight against cancer. [H3] Mission To conquer cancer. By building a sustainable healthcare ecosystem that provide patients with access to better cancer treatment, regardless of their nationality or wealth. [H3] Vision Building a global biotechnology company committed to continued innovation to develop and commercialize pioneering cancer treatments. [H3] Focus Developing new standard of care cancer treatments based on our Alluminox® platform.
3541 chars
SUB-PAGE (https://rakuten-med.com/us/) Rakuten Medical – To conquer cancer.
Image provided by Rush University Medical Center Image provided by Rush University Medical Center [H2] Press Release June 9, 2026 [H3] Rakuten Medical Announces Executive Leadership Transition to Enhance Operational Execution and Organizational Discipline as a Global, Scalable Biotech Company May 30, 2026 [H3] Rakuten Medical Presents New Data on ASP-1929 Photoimmunotherapy as Monotherapy for Recurrent Head and Neck Cancer at ASCO 2026 View all [H2] Rakuten Medical Stories September 19, 2023 [H3] Rakuten Medical’s 2nd R&D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy April 17, 2023 [H3] Rakuten Medical R&D Day shared comprehensive overview of investigational Alluminox™ platform and the promising scientific and clinical data for ASP-1929/RM-1929 based on the platform View all Press Release Rakuten Medical Stories June 9, 2026 [H3] Rakuten Medical Announces Executive Leadership Transition to Enhance Operational Execution and Organizational Discipline as a Global, Scalable Biotech Company May 30, 2026 [H3] Rakuten Medical Presents New Data on ASP-1929 Photoimmunotherapy as Monotherapy for Recurrent Head and Neck Cancer at ASCO 2026 April 30, 2026 [H3] Rakuten Medical Announces Two Poster Presentations and Exhibit Booth at ASCO 2026 Annual Meeting View all September 19, 2023 [H3] Rakuten Medical’s 2nd R&D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy April 17, 2023 [H3] Rakuten Medical R&D Day shared comprehensive overview of investigational Alluminox™ platform and the promising scientific and clinical data for ASP-1929/RM-1929 based on the platform December 5, 2022 [H3] Rakuten Medical aims to transform head and neck cancer treatments in India View all The Alluminox® platform is an investigational platform based on a cancer therapy called photoimmunotherapy, which was developed by Dr. Hisataka Kobayashi and team from the National Cancer Institute in the United States. Rakuten Medical is currently developing the Alluminox® platform as a technology consisting of an investigational drug, device and other related components. Read more [H2] Letter from Our CEO [H3] Help came too late for my father [H2] Letter fromOur CEO [H3] Help came too late for my father While my wish to save my father from the debilitating effects of cancer may have not come true, the experience inspired in me the determination to work to discover new ways to save the lives of other cancer patients around the world. That same determination is the lifeforce behind Rakuten Medical. Read more [H2] Our Mission Our first objective is to create and bring to market drugs and devices to treat cancers based on the Alluminox® platform. Our purpose is to develop the Alluminox® platform as an alternative technology in the fight against cancer. [H3] Mission To conquer cancer. By building a sustainable healthcare ecosystem that provide patients with access to better cancer treatment, regardless of their nationality or wealth. [H3] Vision Building a global biotechnology company committed to continued innovation to develop and commercialize pioneering cancer treatments. [H3] Focus Developing new standard of care cancer treatments based on our Alluminox® platform.
3541 chars
SUB-PAGE (https://rakuten-med.com/us/news/press-releases/) Press Releases – Rakuten Medical – To conquer cancer.
[H1] Press Releases [H2] All June 9, 2026 [H3] Rakuten Medical Announces Executive Leadership Transition to Enhance Operational Execution and Organizational Discipline as a Global, Scalable Biotech Company May 30, 2026 [H3] Rakuten Medical Presents New Data on ASP-1929 Photoimmunotherapy as Monotherapy for Recurrent Head and Neck Cancer at ASCO 2026 April 30, 2026 [H3] Rakuten Medical Announces Two Poster Presentations and Exhibit Booth at ASCO 2026 Annual Meeting April 21, 2026 [H3] Rakuten Medical Presents New Preclinical Findings at AACR 2026 Showing COX‑2 Inhibition Reduces Photoimmunotherapy‑Induced Edema via PGE₂ Suppression February 18, 2026 [H3] Rakuten Medical Announces First Patient Treated in Ukraine in Global Phase 3 Trial of ASP-1929 Photoimmunotherapy + Pembrolizumab for 1L Recurrent Head and Neck Cancer 1 2 3 … 18 Next » [H3] Year Archive 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 [H2] Related Content [H3] Rakuten Medical Stories [H3] Press Kit
1073 chars
SUB-PAGE (https://rakuten-med.com/us/news/stories/) Rakuten Medical Stories – Rakuten Medical – To conquer cancer.
[H1] Rakuten Medical Stories [H2] All [H3] September 19, 2023 Rakuten Medical’s 2nd R&D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy [H3] April 17, 2023 Rakuten Medical R&D Day shared comprehensive overview of investigational Alluminox™ platform and the promising scientific and clinical data for ASP-1929/RM-1929 based on the platform [IMG: Tata-Memorial-Center.jpg] [H3] December 5, 2022 Rakuten Medical aims to transform head and neck cancer treatments in India [IMG: FHNO2022 Rakuten Medical booth.jpg] [H3] November 29, 2022 Mickey Mikitani gives keynote at India Head & Neck Oncology Conference “FHNO2022”, Rakuten Medical also releases new video about the Alluminox™ platform [IMG: J.P. Morgan Global Healthcare Conference.jpg] [H3] December 1, 2021 Rakuten Medical Participates in the J.P. Morgan Global Healthcare Conference, Shanghai Forum [H3] April 22, 2020 Rakuten Medical celebrates its 10-year anniversary 1 2 3 … 6 Next » [H3] Year Archive collapsArch options: Array ( [title] => Year Archive [noTitle] => [inExcludeCat] => exclude [inExcludeCats] => [inExcludeYear] => exclude [inExcludeYears] => [showPages] => [sort] => DESC [linkToArch] => 1 [showYearCount] => [expandCurrentYear] => 1 [expandMonths] => [expandYears] => [expandCurrentMonth] => [showMonthCount] => [showPostTitle] => [expand] => 0 [showPostDate] => [debug] => 1 [postDateFormat] => m/d [postDateAppend] => after [accordion] => 1 [useCookies] => 1 [post_type] => stories [taxoncmy] => category [postTitleLength] => [showPostCount] => 1 [style] => custom [archSortOrder] => DESC [showPosts] => [customExpand] => [customCollapse] => [taxonomy] => both [so_sidebar_emulator_id] => collapsarch-729710003 [option_name] => widget_collapsarch [panels_info] => Array ( [class] => collapsArchWidget [raw] => [grid] => 1 [cell] => 1 [id] => 3 [widget_id] => 89715525-396f-4351-b0e2-b3fc707eb06b [style] => Array ( [class] => year-archive [background_image_attachment] => [background_display] => tile [disable_widget] => [disable_desktop] => [disable_tablet] => [disable_mobile] => [disable_logged_out] => [disable_logged_in] => ) [cell_index] => 0 [widget_index] => 3 ) [number] => 7 ) POST QUERY: SELECT wp_6_terms.slug, wp_6_posts.ID, wp_6_posts.post_name, wp_6_posts.post_title, wp_6_posts.post_author, wp_6_posts.post_date, YEAR(wp_6_posts.post_date) AS 'year', MONTH(wp_6_posts.post_date) AS 'month' , wp_6_posts.post_type FROM wp_6_posts LEFT JOIN wp_6_term_relationships ON wp_6_posts.ID = wp_6_term_relationships.object_id LEFT JOIN wp_6_term_taxonomy ON wp_6_term_taxonomy.term_taxonomy_id = wp_6_term_relationships.term_taxonomy_id LEFT JOIN wp_6_terms ON wp_6_terms.term_id = wp_6_term_taxonomy.term_id WHERE post_status='publish' AND wp_6_posts.post_type='stories' GROUP BY wp_6_posts.ID ORDER BY wp_6_posts.post_date DESC POST QUERY RESULTS Array ( [0] => stdClass Object ( [slug] => rakuten-medical [ID] => 7736 [post_name] => rakuten-medicals-2nd-rd-day-featured-the-preliminary-safety-and-efficacy-data-for-alluminox-treatment-using-asp-1929-in-combination-with-anti-pd-1-therapy [post_title] => Rakuten Medical's 2nd R&D Day featured the preliminary safety and efficacy data for Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy tfiliyas => 4 August 26, 2020 => 2023-09-19 19:29:45 [year] => 2023 [month] => 9 [post_type] => stories ) [1] => stdClass Object ( [slug] => rakuten-medical [ID] => 7700 [post_name] => rakuten-medical-rd-day-shared-comprehensive-overview-of-investigational-alluminox-platform-and-the-promising-scientific-and-clinical-data-for-asp-1929-rm-1929-based-on-the-platform [post_title] => Rakuten Medical R&D Day shared comprehensive overview of investigational Alluminox™ platform and the promising scientific and clinical data for ASP-1929/RM-1929 based on the platform tfiliyas => 4 August 26, 2020 => 2023-04-17 18:32:53 [year] => 2023 [month] => 4 [post_type] => stories ) [2] => stdClass Object ( [slug] => rakuten-medical [ID] => 7613 [post_name] => rakuten-medical-aims-to-transform-head-and-neck-cancer-treatments-in-india [post_title] => Rakuten Medical aims to transform head and neck cancer treatments in India tfiliyas => 4 August 26, 2020 => 2022-12-05 17:00:17 [year] => 2022 [month] => 12 [post_type] => stories ) [3] => stdClass Object ( [slug] => rakuten-medical [ID] => 7605 [post_name] => mickey-mikitani-gives-keynote-at-india-head-neck-oncology-conference-fhno2022-rakuten-medical-also-releases-new-video-about-the-alluminox-platform [post_title] => Mickey Mikitani gives keynote at India Head & Neck Oncology Conference “FHNO2022”, Rakuten Medical also releases new video about the Alluminox™ platform tfiliyas => 4 August 26, 2020 => 2022-11-29 18:00:11 [year] => 2022 [month] => 11 [post_type] => stories ) [4] => stdClass Object ( [slug] => rakuten-medical [ID] => 7545 [post_name] => rakuten-medical-participates-in-the-j-p-morgan-global-healthcare-conference-shanghai-forum [post_title] => Rakuten Medical Participates in the J.P. Morgan Global Healthcare Conference, Shanghai Forum tfiliyas => 4 August 26, 2020 => 2021-12-01 02:54:29 [year] => 2021 [month] => 12 [post_type] => stories ) [5] => stdClass Object ( [slug] => rakuten-medical [ID] => 7088 [post_name] => rakuten-medical-celebrates-its-10-year-anniversary [post_title] => Rakuten Medical celebrates its 10-year anniversary tfiliyas => 4 August 26, 2020 => 2020-04-22 22:53:13 [year] => 2020 [month] => 4 [post_type] => stories ) [6] => stdClass Object ( [slug] => rakuten [ID] => 7076 [post_name] => a-decade-of-disruption-5-tech-storylines-set-to-define-2020-and-beyond [post_title] => A decade of disruption: 5 tech storylines set to define 2020 and beyond tfiliyas => 12 August 26, 2020 => 2020-01-10 13:43:25 [year] => 2020 [month] => 1 [post_type] => stories ) [7] => stdClass Object ( [slug] => investment [ID] => 7075 [post_name] => 38th-annual-j-p-morgan-healthcare-conference [post_title] => 38th Annual J.P. Morgan Healthcare Conference tfiliyas => 4 August 26, 2020 => 2020-01-10 10:22:25 [year] => 2020 [month] => 1 [post_type] => stories ) [8] => stdClass Object ( [slug] => rakuten [ID] => 7077 [post_name] => the-19-billion-dollar-startups-to-watch-that-are-revolutionizing-healthcare-in-2020 [post_title] => The 19 billion-dollar startups to watch that are revolutionizing healthcare in 2020 tfiliyas => 12 August 26, 2020 => 2020-01-03 16:58:45 [year] => 2020 [month] => 1 [post_type] => stories ) [9] => stdClass Object ( [slug] => amsterdam [ID] => 7073 [post_name] => in-the-wake-of-brexit-amsterdam-is-the-new-london [post_title] => In the Wake of Brexit, Amsterdam Is the New London tfiliyas => 12 August 26, 2020 => 2019-12-02 17:34:58 [year] => 2019 [month] => 12 [post_type] => stories ) [10] => stdClass Object ( [slug] => rakuten [ID] => 7072 [post_name] => top-10-immuno-oncology-startups-of-2019 [post_title] => Top 10 Immuno-Oncology Startups of 2019 tfiliyas => 12 August 26, 2020 => 2019-12-02 17:31:51 [year] => 2019 [month] => 12 [post_type] => stories ) [11] => stdClass Object ( [slug] => rakuten-medical [ID] => 7068 [post_name] => rakuten-anti-cancer-therapy-candidate-to-activate-immune-system-response [post_title] => Rakuten anti-cancer therapy candidate to activate immune system response tfiliyas => 2 August 26, 2020 => 2019-11-18 14:41:08 [year] => 2019 [month] => 11 [post_type] => stories ) [12] => stdClass Object ( [slug] => rakuten [ID] => 7063 [post_name] => walk-together-rakuten-ceo-shares-vision-for-the-future-at-rakuten-optimism-in-san-francisco [post_title] => WALK TOGETHER: RAKUTEN CEO SHARES VISION FOR THE FUTURE AT RAKUTEN OPTIMISM IN SAN FRANCISCO tfiliyas => 2 August 26, 2020 => 2019-11-11 15:26:10 [year] => 2019 [month] => 11 [post_type] => stories ) [13] => stdClass Object ( [slug] => rakuten-medical [ID] => 7069 [post_name] => rakuten-medical-releases-new-post-hoc-analysis-of-safety-pharmacokinetic-pk-immunogenicity-and-biomarker-data-from-its-phase-1-1-2a-clinical-trials [post_title] => Rakuten Medical Releases New, Post-hoc Analysis of Safety, Pharmacokinetic (PK), Immunogenicity and Biomarker Data from its Phase 1 & 1/2a Clinical Trials tfiliyas => 2 August 26, 2020 => 2019-11-05 14:43:37 [year] => 2019 [month] => 11 [post_type] => stories ) [14] => stdClass Object ( [slug] => 2019 [ID] => 7053 [post_name] => jefferies-2019-london-healthcare [post_title] => Jefferies 2019 London Healthcare Conference tfiliyas => 12 August 26, 2020 => 2019-11-04 16:22:43 [year] => 2019 [month] => 11 [post_type] => stories ) [15] => stdClass Object ( [slug] => life [ID] => 7052 [post_name] => investival-showcase [post_title] => Investival Showcase tfiliyas => 12 August 26, 2020 => 2019-11-04 16:18:35 [year] => 2019 [month] => 11 [post_type] => stories ) [16] => stdClass Object ( [slug] => cancer [ID] => 7050 [post_name] => sitc-annual-meeting-2019 [post_title] => SITC Annual Meeting 2019 tfiliyas => 12 August 26, 2020 => 2019-11-01 14:02:54 [year] => 2019 [month] => 11 [post_type] => stories ) [17] => stdClass Object ( [slug] => rakuten-medical [ID] => 7046 [post_name] => rakuten-medical-to-further-develop-its-photoimmunotherapy [post_title] => Rakuten Medical to further develop its photoimmunotherapy tfiliyas => 12 August 26, 2020 => 2019-10-26 21:05:02 [year] => 2019 [month] => 10 [post_type] => stories ) [18] => stdClass Object ( [slug] => rakuten [ID] => 7045 [post_name] => rakuten-medical-extends-series-c-treatment-by-100m [post_title] => Rakuten Medical extends series C treatment by $100m tfiliyas => 12 August 26, 2020 => 2019-10-26 21:02:37 [year] => 2019 [month] => 10 [post_type] => stories ) [19] => stdClass Object ( [slug] => rakuten-medical [ID] => 7044 [post_name] => ecommerce-company-rakuten-invests-100-million-in-rakuten-medical-increasing-equity-share-to-22-5 [post_title] => Ecommerce Company Rakuten Invests $100 Million in Rakuten Medical, Increasing Equity Share to 22.5% tfiliyas => 12 August 26, 2020 => 2019-10-26 21:01:12 [year] => 2019 [month] => 10 [post_type] => stories ) [20] => stdClass Object ( [slug] => rakuten-medical [ID] => 7043 [post_name] => rakuten-medical-secures-additional-investment-from-rakuten [post_title] => Rakuten Medical secures additional investment from Rakuten tfiliyas => 12 August 26, 2020 => 2019-10-26 20:59:11 [year] => 2019 [month] => 10 [post_type] => stories ) [21] => stdClass Object ( [slug] => [ID] => 7042 [post_name] => at-newly-rechristened-rakuten-medical-japanese-billionaire-mikitani-ups-the-ante-with-another-megaround [post_title] => At newly rechristened Rakuten Medical, Japanese billionaire Mikitani ups the ante with another megaround tfiliyas => 12 August 26, 2020 => 2019-10-26 20:57:08 [year] => 2019 [month] => 10 [post_type] => stories ) [22] => stdClass Object ( [slug] => rakuten-medical [ID] => 7041 [post_name] => rakuten-medical-reels-in-another-megaround-to-fund-cancer-rd [post_title] => Rakuten Medical reels in another megaround to fund cancer R&D tfiliyas => 12 August 26, 2020 => 2019-10-26 20:54:06 [year] => 2019 [month] => 10 [post_type] => stories ) [23] => stdClass Object ( [slug] => tumors [ID] => 7039 [post_name] => u-s-clinical-trial-light-therapy-kills-cancer-cells-in-4-of-30-patients [post_title] => U.S. clinical trial: Light therapy kills cancer cells in 4 of 30 patients tfiliyas => 12 August 26, 2020 => 2019-10-26 20:48:37 [year] => 2019 [month] => 10 [post_type] => stories ) [24] => stdClass Object ( [slug] => rakuten [ID] => 7038 [post_name] => online-retailer-rakutens-biotech-offices-in-taiwan-amsterdam-to-speed-up-anti-cancer-drug-development [post_title] => Online retailer Rakuten’s biotech offices in Taiwan, Amsterdam to speed up anti-cancer drug development tfiliyas => 12 August 26, 2020 => 2019-10-26 20:46:49 [year] => 2019 [month] => 10 [post_type] => stories ) [25] => stdClass Object ( [slug] => rakuten-medical [ID] => 7037 [post_name] => rakuten-medical-opens-european-headquarters-in-the-netherlands [post_title] => Rakuten Medical Opens European Headquarters in the Netherlands tfiliyas => 12 August 26, 2020 => 2019-10-26 20:44:56 [year] => 2019 [month] => 10 [post_type] => stories ) [26] => stdClass Object ( [slug] => pit [ID] => 7036 [post_name] => rakuten-medical-releases-phase-2a-study-data-during-asco-annual-meeting-highlighting-positive-safety-profile-and-clinically-meaningful-anti-tumor-activity [post_title] => Rakuten Medical Releases Phase 2a Study Data during ASCO Annual Meeting Highlighting Positive Safety Profile and Clinically Meaningful Anti-tumor Activity tfiliyas => 12 August 26, 2020 => 2019-10-26 20:40:31 [year] => 2019 [month] => 10 [post_type] => stories ) [27] => stdClass Object ( [slug] => rakuten [ID] => 7035 [post_name] => rakuten-medical-opens-two-new-offices-as-it-expands-global-presence [post_title] => Rakuten Medical opens two new offices as it expands global presence tfiliyas => 12 August 26, 2020 => 2019-10-26 20:38:48 [year] => 2019 [month] => 10 [post_type] => stories ) [28] => stdClass Object ( [slug] => cancer [ID] => 7034 [post_name] => japan-approves-rakuten-medicals-asp-1929-to-treat-cancer [post_title] => Japan approves Rakuten Medical's ASP-1929 to treat cancer tfiliyas => 12 August 26, 2020 => 2019-10-26 20:36:29 [year] => 2019 [month] => 10 [post_type] => stories ) [29] => stdClass Object ( [slug] => rakuten [ID] =&g
15000 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
8Review mentions (all pages)
0External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 2 | 0 |
| /us/ | 2 | 0 |
| /us/news/press-releases/ | 2 | 0 |
| /us/news/stories/ | 2 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://rakuten-med.com/us/",
"url": "https://rakuten-med.com/us/",
"name": "Rakuten Medical - To conquer cancer.",
"isPartOf": {
"@id": "https://rakuten-med.com/us/#website"
},
"primaryImageOfPage": {
"@id": "https://rakuten-med.com/us/#primaryimage"
},
"image": {
"@id": "https://rakuten-med.com/us/#primaryimage"
},
"thumbnailUrl": "https://rakuten-med.com/us/wp-content/uploads/sites/6/2021/02/RakutenMedical_KV.png",
"datePublished": "2020-08-14T19:07:52+00:00",
"dateModified": "2026-02-24T17:52:31+00:00",
"description": "Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox™ technology platform which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis.Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives.",
"breadcrumb": {
"@id": "https://rakuten-med.com/us/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://rakuten-med.com/us/"
]
}
]
},
{
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "https://rakuten-med.com/us/#primaryimage",
"url": "https://rakuten-med.com/us/wp-content/uploads/sites/6/2021/02/RakutenMedical_KV.png",
"contentUrl": "https://rakuten-med.com/us/wp-content/uploads/sites/6/2021/02/RakutenMedical_KV.png",
"width": 1500,
"height": 900
},
{
"@type": "BreadcrumbList",
"@id": "https://rakuten-med.com/us/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home"
}
]
},
{
"@type": "WebSite",
"@id": "https://rakuten-med.com/us/#website",
"url": "https://rakuten-med.com/us/",
"name": "Rakuten Medical - To conquer cancer.",
"description": "Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox™TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.",
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://rakuten-med.com/us/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
}
]
}
/us/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://rakuten-med.com/us/",
"url": "https://rakuten-med.com/us/",
"name": "Rakuten Medical - To conquer cancer.",
"isPartOf": {
"@id": "https://rakuten-med.com/us/#website"
},
"primaryImageOfPage": {
"@id": "https://rakuten-med.com/us/#primaryimage"
},
"image": {
"@id": "https://rakuten-med.com/us/#primaryimage"
},
"thumbnailUrl": "https://rakuten-med.com/us/wp-content/uploads/sites/6/2021/02/RakutenMedical_KV.png",
"datePublished": "2020-08-14T19:07:52+00:00",
"dateModified": "2026-02-24T17:52:31+00:00",
"description": "Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox™ technology platform which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis.Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives.",
"breadcrumb": {
"@id": "https://rakuten-med.com/us/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://rakuten-med.com/us/"
]
}
]
},
{
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "https://rakuten-med.com/us/#primaryimage",
"url": "https://rakuten-med.com/us/wp-content/uploads/sites/6/2021/02/RakutenMedical_KV.png",
"contentUrl": "https://rakuten-med.com/us/wp-content/uploads/sites/6/2021/02/RakutenMedical_KV.png",
"width": 1500,
"height": 900
},
{
"@type": "BreadcrumbList",
"@id": "https://rakuten-med.com/us/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home"
}
]
},
{
"@type": "WebSite",
"@id": "https://rakuten-med.com/us/#website",
"url": "https://rakuten-med.com/us/",
"name": "Rakuten Medical - To conquer cancer.",
"description": "Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox™TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.",
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://rakuten-med.com/us/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
}
]
}
/us/news/press-releases/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://rakuten-med.com/us/news/press-releases/",
"url": "https://rakuten-med.com/us/news/press-releases/",
"name": "Press Releases - Rakuten Medical - To conquer cancer.",
"isPartOf": {
"@id": "https://rakuten-med.com/us/#website"
},
"primaryImageOfPage": {
"@id": "https://rakuten-med.com/us/news/press-releases/#primaryimage"
},
"image": {
"@id": "https://rakuten-med.com/us/news/press-releases/#primaryimage"
},
"thumbnailUrl": "https://rakuten-med.com/us/wp-content/uploads/sites/6/2020/08/press-release-banner.png",
"datePublished": "2020-08-21T05:42:43+00:00",
"dateModified": "2024-09-10T06:44:55+00:00",
"breadcrumb": {
"@id": "https://rakuten-med.com/us/news/press-releases/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://rakuten-med.com/us/news/press-releases/"
]
}
]
},
{
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "https://rakuten-med.com/us/news/press-releases/#primaryimage",
"url": "https://rakuten-med.com/us/wp-content/uploads/sites/6/2020/08/press-release-banner.png",
"contentUrl": "https://rakuten-med.com/us/wp-content/uploads/sites/6/2020/08/press-release-banner.png",
"width": 1400,
"height": 540
},
{
"@type": "BreadcrumbList",
"@id": "https://rakuten-med.com/us/news/press-releases/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://rakuten-med.com/us/"
},
{
"@type": "ListItem",
"position": 2,
"name": "News",
"item": "https://rakuten-med.com/us/news/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Press Releases"
}
]
},
{
"@type": "WebSite",
"@id": "https://rakuten-med.com/us/#website",
"url": "https://rakuten-med.com/us/",
"name": "Rakuten Medical - To conquer cancer.",
"description": "Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox™TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.",
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://rakuten-med.com/us/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
}
]
}
/us/news/stories/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://rakuten-med.com/us/news/stories/",
"url": "https://rakuten-med.com/us/news/stories/",
"name": "Rakuten Medical Stories - Rakuten Medical - To conquer cancer.",
"isPartOf": {
"@id": "https://rakuten-med.com/us/#website"
},
"primaryImageOfPage": {
"@id": "https://rakuten-med.com/us/news/stories/#primaryimage"
},
"image": {
"@id": "https://rakuten-med.com/us/news/stories/#primaryimage"
},
"thumbnailUrl": "https://rakuten-med.com/us/wp-content/uploads/sites/6/2020/09/stories_top_5.jpg",
"datePublished": "2020-08-27T04:59:30+00:00",
"dateModified": "2024-09-10T06:45:40+00:00",
"breadcrumb": {
"@id": "https://rakuten-med.com/us/news/stories/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://rakuten-med.com/us/news/stories/"
]
}
]
},
{
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "https://rakuten-med.com/us/news/stories/#primaryimage",
"url": "https://rakuten-med.com/us/wp-content/uploads/sites/6/2020/09/stories_top_5.jpg",
"contentUrl": "https://rakuten-med.com/us/wp-content/uploads/sites/6/2020/09/stories_top_5.jpg",
"width": 1399,
"height": 419
},
{
"@type": "BreadcrumbList",
"@id": "https://rakuten-med.com/us/news/stories/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://rakuten-med.com/us/"
},
{
"@type": "ListItem",
"position": 2,
"name": "News",
"item": "https://rakuten-med.com/us/news/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Rakuten Medical Stories"
}
]
},
{
"@type": "WebSite",
"@id": "https://rakuten-med.com/us/#website",
"url": "https://rakuten-med.com/us/",
"name": "Rakuten Medical - To conquer cancer.",
"description": "Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox™TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.",
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://rakuten-med.com/us/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
}
]
}
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Information Density
0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence
0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof
0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint
0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority
0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score
0 / 100
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Information Density
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Semantic Alignment
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Trust & Proof
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Commodity Fingerprint
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Identity & Authority
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS
Based on 784 businesses audited.
BS Detector
Medical Devices, Pharma & Biotech BS: Rakuten Medical, Inc. (rakuten-med.com)
https://rakuten-med.com
📍 Industry: Medical Devices, Pharma & Biotech
32
BS / 100
Rakuten Medical is a rare example of a high-substance biotech site where the ‘Signal’ of conquering cancer is backed by the ‘Substance’ of a named, dated, and active clinical pipeline. The low BS score reflects a professional commitment to technical transparency over marketing hyperbole. The only significant ‘hot air’ is the minor trust theatre in the review/proof count ratio.
Info Density
Power-words vs. Substance ratio.
8
27% BS
Semantic Coherence
Homepage promise vs. Sub-page reality.
0
0% BS
Trust & Proof
Verifiable evidence vs. Trust Theatre.
12
60% BS
Commodity Fingerprint
Detection of industry clichés/templates.
6
40% BS
Identity & Authority
Expert verifiability & Schema depth.
6
40% BS
First, integrate Organization and Person schema to include sameAs links for Dr. Kobayashi and the executive team to solidify authority. Second, replace the internal Stories links with direct outbound proof paths to the actual ASCO and AACR poster presentations or peer-reviewed journals. Third, resolve the trust theatre flag by ensuring every review or testimonial is accompanied by a verifiable link to a third-party source or clinical trial registry. Fourth, add specific patent numbers and regulatory status IDs (e.g., FDA Orphan Drug Designation numbers) directly to the Pipeline or Alluminox body text.
The site perfectly aligns with the Medical Devices, Pharma & Biotech category. It focuses heavily on its proprietary Alluminox platform, clinical trial data (ASP-1929), and regulatory milestones like ASCO 2026 presentations.
“The score of 32 was driven primarily by Trust and Proof gaps (lack of outbound proof links) and Identity and Authority gaps (basic schema). Information Density is high, and Semantic Coherence is perfect, preventing the score from reaching the 'Moderate BS' range. The site is a benchmark for pharmaceutical substance in digital presence.”
Verified Analysis Date: June 19, 2026
© 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution
This training module utilizes a snapshot of public data from Rakuten Medical, Inc., captured on June 19, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Rakuten Medical, Inc.: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://rakuten-med.com to view the most current version of its content and learn from the source what this company is about and what it offers.